Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Bone Marrow Transplant. 2010 Dec 13;46(10):1382–1388. doi: 10.1038/bmt.2010.301

Table 2.

In vitro characteristics of ECP PBMC:

In vitro study Pre-ECP PBMC Post-ECP PBMC Pre-ECP BC Post-ECP BC
Mixed leukocyte culture:
% Alloreactivity, median, (range) 100% 92.1(59.32–178.2) 48.7(21.3–375) 3.5(0.08–19.6)
NK-cell function:
% specific lysis, median, (range) 53.8 (14–57.3) 32 (28–57) 38.7 (16.2–50.4) 16.6 (8.7–33.2)
Apoptosis-early:
% Annexin-V FITC+/Pl− Mean, (standard deviation) 14.4 (5.2–23.6) 16.9 (5.3–29.1) 25 (15.4–40) 34.5 (10.6–5.3)
Apoptosis-late:
% Annexin-V FITC+/Pl− Mean, (standard deviation) 16.2 (6.5–27.7) 19.1 (7.9–32.7) 31.2 (15.4–40) 65.2 (45.8–81.3)